<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">43362</article-id><article-id pub-id-type="doi">10.7554/eLife.43362</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>The <italic>Plasmodium</italic> Liver-Specific Protein 2 (LISP2) is an early marker of liver stage development</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-91328"><name><surname>Gupta</surname><given-names>Devendra Kumar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-125082"><name><surname>Dembele</surname><given-names>Laurent</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-91327"><name><surname>Voorberg-van der Wel</surname><given-names>Annemarie</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9403-0515</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-56972"><name><surname>Roma</surname><given-names>Guglielmo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8020-4219</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-125077"><name><surname>Yip</surname><given-names>Andy</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-125079"><name><surname>Chuenchob</surname><given-names>Vorada</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-119866"><name><surname>Kangwanrangsan</surname><given-names>Niwat</given-names></name><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-125080"><name><surname>Ishino</surname><given-names>Tomoko</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2466-711X</contrib-id><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-125081"><name><surname>Vaughan</surname><given-names>Ashley M</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-91363"><name><surname>Kappe</surname><given-names>Stefan HI</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1540-1731</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-119228"><name><surname>Flannery</surname><given-names>Erika L</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-0665-7954</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-119867"><name><surname>Sattabongkot</surname><given-names>Jetsumon</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3938-4588</contrib-id><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-119229"><name><surname>Mikolajczak</surname><given-names>Sebastian A</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-125078"><name><surname>Bifani</surname><given-names>Pablo</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-91338"><name><surname>Kocken</surname><given-names>Clemens H M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-90412"><name><surname>Diagana</surname><given-names>Thierry Tidiane</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8520-5683</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf8"/></contrib><aff id="aff1"><institution>Novartis Institute for Tropical Diseases</institution>, <addr-line><named-content content-type="city">Emeryville</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Faculty of Pharmacy</institution>, <institution>Université des Sciences, des Techniques et des Technologies de Bamako</institution>, <addr-line><named-content content-type="city">Bamako</named-content></addr-line>, <country>Mali</country></aff><aff id="aff3"><institution content-type="dept">Department of Parasitology</institution>, <institution>Biomedical Primate Research Centre</institution>, <addr-line><named-content content-type="city">Rijswijk</named-content></addr-line>, <country>Netherlands</country></aff><aff id="aff4"><institution content-type="dept">Chemical Biology and Therapeutics</institution>, <institution>Novartis Institutes for BioMedical Research</institution>, <addr-line><named-content content-type="city">Basel</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff5"><institution>Novartis Institute for Tropical Diseases</institution>, <addr-line><named-content content-type="city">Singapore</named-content></addr-line>, <country>Singapore</country></aff><aff id="aff6"><institution>Center for Infectious Disease Research</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff><aff id="aff7"><institution content-type="dept">Department of Pathobiology, Faculty of Science</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff><aff id="aff8"><institution>Ehime University</institution>, <addr-line><named-content content-type="city">Ehime</named-content></addr-line>, <country>Japan</country></aff><aff id="aff9"><institution content-type="dept">Mahidol Vivax Research Unit, Faculty of Tropical Medicine</institution>, <institution>Mahidol University</institution>, <addr-line><named-content content-type="city">Bangkok</named-content></addr-line>, <country>Thailand</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-21294"><name><surname>Krzych</surname><given-names>Urszula</given-names></name><role>Reviewing editor</role><aff><institution>Walter Reed Army Institute of Research</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>thierry.diagana@novartis.com</email> (TD);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>05</month><year>2019</year></pub-date><volume>8</volume><elocation-id>e43362</elocation-id><history><date date-type="received"><day>09</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>13</day><month>05</month><year>2019</year></date></history><permissions><copyright-statement>© 2019, Gupta et al</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>Gupta et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-43362-v1.pdf"/><abstract><p><italic>Plasmodium vivax</italic> hypnozoites persist in the liver, cause malaria relapse and represent a major challenge to malaria elimination. Our previous transcriptomic study provided a novel molecular framework to enhance our understanding of the hypnozoite biology (Voorberg-van der Wel A, et al., 2017). In this dataset, we identified and characterized the Liver-Specific Protein 2 (LISP2) protein as an early molecular marker of liver stage development. Immunofluorescence analysis of hepatocytes infected with relapsing malaria parasites, <italic>in vitro </italic>(<italic>P. cynomolgi</italic>) and <italic>in vivo</italic> (<italic>P. vivax</italic>), reveals that LISP2 expression discriminates between dormant hypnozoites and early developing parasites. We further demonstrate that prophylactic drugs selectively kill all LISP2 positive parasites, while LISP2 negative hypnozoites are only sensitive to anti-relapse drug tafenoquine. Our results provide novel biological insights in the initiation of liver stage schizogony and an early marker suitable for the development of drug discovery assays predictive of anti-relapse activity.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Other</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>OPP1141292</award-id><principal-award-recipient><name><surname>Roma</surname><given-names>Guglielmo</given-names></name><name><surname>Kocken</surname><given-names>Clemens H M</given-names></name><name><surname>Diagana</surname><given-names>Thierry Tidiane</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>OPP1137694</award-id><principal-award-recipient><name><surname>Mikolajczak</surname><given-names>Sebastian A</given-names></name></principal-award-recipient></award-group><funding-statement>Funders have no role in the design of the study.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Devendra Kumar Gupta, is employed by and/or shareholder of Novartis Pharma AG.</p></fn><fn fn-type="conflict" id="conf3"><p>Guglielmo Roma, is employed by and/or shareholder of Novartis Pharma AG.</p></fn><fn fn-type="conflict" id="conf4"><p>Andy Yip, is employed by and/or shareholder of Novartis Pharma AG.</p></fn><fn fn-type="conflict" id="conf5"><p>Erika L Flannery, is employed by and/or shareholder of Novartis Pharma AG.</p></fn><fn fn-type="conflict" id="conf6"><p>Sebastian A Mikolajczak, is employed by and/or shareholder of Novartis Pharma AG.</p></fn><fn fn-type="conflict" id="conf7"><p>Pablo Bifani, is employed by and/or shareholder of Novartis Pharma AG.</p></fn><fn fn-type="conflict" id="conf8"><p>Thierry Tidiane Diagana, is employed by and/or shareholder of Novartis Pharma AG..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Ethics statement included in the method section of the manuscript.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated during the study are submitted as supplementary source files.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Voorberg-van der Wel A</collab><collab>Roma G</collab><collab>Gupta DV</collab><collab>Schuierer S</collab><collab>Nigsch F</collab><collab>Carbone W</collab><collab>Zeeman A-M</collab><collab>Lee BH</collab><collab>Hofman SD</collab><collab>Faber BW</collab><collab>Knehr J</collab><collab>Pasini EM</collab><collab>Kinzel B</collab><collab>Bifani P</collab><collab>Bonamy GMC</collab><collab>Bouwmeester T</collab><collab>Kocken CHM</collab><collab>Diagana TT</collab></person-group><year iso-8601-date="2017">2017</year><source>Malaria Liver Stages Transcriptome</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sra/?term=SRP096160">https://www.ncbi.nlm.nih.gov/sra/?term=SRP096160</ext-link><comment>NCBI Sequence Read Archive, SRP096160</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-43362-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>